The interim period for the fiscal year ending December 2026 shows net sales of 20,820 thousand yen, operating loss of 570,958 thousand yen, ordinary loss of 576,215 thousand yen, and interim net loss of 610,611 thousand yen. Compared with the same period last year, sales decreased while the magnitude of losses narrowed. The company continues efforts to advance its regenerative medicine business and cell sheet regenerative medicine business, along with funding activities. Cash flow is stable, but the timing of approvals and monetization for the first product remains uncertain.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"7776","jir_company_name":"CellSeed Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-13","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/7776-20260813-01.pdf","jir_short_summary":"The interim period for the fiscal year ending December 2026 shows net sales of 20,820 thousand yen, operating loss of 570,958 thousand yen, ordinary loss of 576,215 thousand yen, and interim net loss of 610,611 thousand yen. Compared with the same period last year, sales decreased while the magnitude of losses narrowed. The company continues efforts to advance its regenerative medicine business and cell sheet regenerative medicine business, along with funding activities. Cash flow is stable, but the timing of approvals and monetization for the first product remains uncertain.","jir_summary":"### Overview of performance\nCellSeed recorded net sales of 20,820 thousand yen in the interim period, down year over year. Operating loss was 570,958 thousand yen, ordinary loss 576,215 thousand yen, and interim net loss 610,611 thousand yen, continuing to post deficits. Both the Regenerative Medicine Support Business and the Cell Sheet Regenerative Medicine Business are pursuing sales growth, with particular emphasis on the Phase 3 trial for allogeneic chondrocyte sheet (CLS2901C); timing for approval and monetization remains uncertain. Cash on hand is stabilized by funds raised through exercise of new stock acquisition rights.\n\n### Outlook and impact for investors\nFull-year earnings guidance remains unchanged from the time of release. Accelerating commercialization of the first product and pursuing business collaborations are key to realizing revenue opportunities; the formation of partnerships and progress of clinical trials are critical. While the financial position has been strengthened by capital proceeds from the exercise of stock acquisition rights, uncertainty remains until approval and monetization, so investors should monitor R&D progress and liquidity stability.","jir_financial_highlights":"Net sales: 20,820\u5343\u5186 (Year-over-year decrease of 16,178\u5343\u5186)\nOperating loss: 570,958\u5343\u5186 (Year-over-year decrease of 52,312\u5343\u5186)\nOrdinary loss: 576,215\u5343\u5186 (Year-over-year decrease of 47,753\u5343\u5186)\nInterim net loss: 610,611\u5343\u5186 (Year-over-year decrease of 40,550\u5343\u5186)\nCash and deposits: 1,792,266\u5343\u5186 (Compared with end of previous fiscal year +473,356\u5343\u5186)","jir_category":"","jir_hashtags":"#CellSeed, #FinancialResults","jir_key_figures":"Net sales: 20,820\u5343\u5186 (YoY: -16,178\u5343\u5186)\nInterim net loss: 610,611\u5343\u5186 (YoY: -40,550\u5343\u5186)\nCash and deposits: 1,792,266\u5343\u5186 (YoY end of previous term +473,356\u5343\u5186)","jir_meta_title":"CellSeed: Interim Results See Red Ink but Stable Funding | FY2026 December Term","jir_meta_description":"Overview of CellSeed's interim results for the fiscal year ending December 2026. Net sales stand at 20,820 thousand yen; operating loss is 570,958 thousand yen; liquidity is stable. Focus moving forward on first product approval\/ monetization and business partnerships.","jir_og_title":"CellSeed Interim Results: Stable Funding, Approval Progress key","jir_og_description":"CellSeed's interim results show net sales of 20,820 thousand yen and net loss in the hundreds of millions of yen. Cash increased due to financing. Watch for progress on approval and monetization of the first product.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59075,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-103587","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n